Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective

por Ahmadiani, Saeed, Nikfar, Shekoufeh
Publicado 2016

Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions

por Abdollahias, Akbar, Nikfar, Shekoufeh, Abdollahi, Mohammad
Publicado 2011

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis

por Rezaie, Ali, Nikfar, Shekoufeh, Abdollahi, Mohammad
Publicado 2010

Are probiotics effective in management of irritable bowel syndrome?

por Hosseini, Asieh, Nikfar, Shekoufeh, Abdollahi, Mohammad
Publicado 2012

Current opinion on treatment of inflammatory bowel disease in pregnant women

por Salari, Pooneh, Nikfar, Shekoufeh, Abdollahi, Mohammad
Publicado 2012

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients

por Mozaffari, Shilan, Nikfar, Shekoufeh, Abdollahi, Mohammad
Publicado 2014

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran

por Aajami, Zahra, Kebriaeezadeh, Abbas, Nikfar, Shekoufeh
Publicado 2019

Short and long term impacts of COVID-19 on the pharmaceutical sector

por Ayati, Nayyereh, Saiyarsarai, Parisa, Nikfar, Shekoufeh
Publicado 2020

Achieving Equitable Access to Medicines and Health Services: A COVID-19-time Recalled Matter

por Mousavi, Taraneh, Nikfar, Shekoufeh, Abdollahi, Mohammad
Publicado 2021

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials

por Nikfar, Shekoufeh, Ehteshami-Afshar, Solmaz, Abdollahi, Mohammad
Publicado 2013

Evaluation of prescriptions of medicines not included in Iran medicine list: A cross-sectional study

por Zargaran, Marzieh, Nikfar, Shekoufeh, Cheraghali, Abdol Majid
Publicado 2016

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran

por Nikfar, Shekoufeh, Kebriaeezadeh, Abbas, Majdzadeh, Reza, Abdollahi, Mohammad
Publicado 2005

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis

por Nikfar, Shekoufeh, Rahimi, Roja, Rezaie, Ali, Abdollahi, Mohammad
Publicado 2010

Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated met...

por Nikfar, Shekoufeh, Rahimi, Roja, Hendoiee, Narjes, Abdollahi, Mohammad
Publicado 2012

Pharmaceutical supply chain risks: a systematic review

por Jaberidoost, Mona, Nikfar, Shekoufeh, Abdollahiasl, Akbar, Dinarvand, Rassoul
Publicado 2013

Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis

por Zaboli, Pardis, Abdollahi, Mohammad, Mozaffari, Shilan, Nikfar, Shekoufeh
Publicado 2017

A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease

por Ehteshami-Afshar, Solmaz, Nikfar, Shekoufeh, Rezaie, Ali, Abdollahi, Mohammad
Publicado 2011

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis

por Ayati, Nayyereh, Taheri, Saeed, Sahraian, Mohammad Ali, Nikfar, Shekoufeh
Publicado 2021

Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

por Tajik, Amirmohammad, Nikfar, Shekoufeh, Elyasi, Sepideh, Rajabi, Omid, Varmaghani, Mehdi
Publicado 2023

A model for developing a decision support system to simulate national drug policy indicators

por Abdollahiasl, Akbar, Nikfar, Shekoufeh, Kebriaeezadeh, Abbas, Dinarvand, Rasoul, Abdollahi, Mohammad
Publicado 2011